Slides - Oncology Nurse Advisor

Slides

Varenicline (Chantix)

  This slideshow reviews varenicline (chantix), indicated as an aid to smoking cessation treatment. Table of Contents Slide 5: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 28: Reference   

Talimogene Laherparepvec (Imlygic)

  This slideshow reviews talimogene laherparepvec (Imlygic), indicated for unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery/ Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 26: Reference   

Belinostat (Beleodaq)

This slideshow reviews belinostat (Beleodaq), indicated for relapsed or refractory peripheral T-cell lymphoma (PTCL). Table of Contents Slide 4: Dosage and AdministrationSlide 12: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 24: Reference 

Osimertinib (Tagrisso)

This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 22: What to Tell Your PatientSlide 29: Reference 

Palbociclib (Ibrance)

This slideshow reviews palbociclib (Ibrance), indicated for Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer . Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference 

Ceritinib (Zykadia)

This slideshow reviews ceritinib (Zykadia), indicated for metastatic non-small cell lung cancer (NSCLC) in patients with ALK-positive tumors. Table of Contents Slide 4: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 23: What to Tell Your PatientSlide 32: Reference   

Ruxolitinib (Jakafi)

This slideshow reviews ruxolitinib (Jakafi), indicated for intermediate or high-risk myelofibrosis, and polycythemia vera in cases of inadequate response or intolerance of hydroxyurea. Table of Contents Slide 4: Dosage and AdministrationSlide 17: Cautions, Effects, and InteractionsSlide 24: What to Tell Your PatientSlide 29: Reference

Acalabrutinib (Calquence)

  This slideshow reviews acalabrutinib (Calquence), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 17: What to Tell Your PatientSlide 23: Reference  

Decitabine (Dacogen)

This slideshow reviews decitabine (Dacogen), indicated for the treatment of myelodysplastic syndrome (MDS). Table of Contents Slide 5: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 24: Reference

Next hm-slideshow in Slides